» Articles » PMID: 36869246

Comparative Thermodynamics of the Reversible Self-Association of Therapeutic MAbs Reveal Opposing Roles for Linked Proton- and Ion-Binding Events

Overview
Journal Pharm Res
Specialties Pharmacology
Pharmacy
Date 2023 Mar 3
PMID 36869246
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Reversible self-association (RSA) has long been a concern in therapeutic monoclonal antibody (mAb) development. Because RSA typically occurs at high mAb concentrations, accurate assessment of the underlying interaction parameters requires explicitly addressing hydrodynamic and thermodynamic nonideality. We previously examined the thermodynamics of RSA for two mAbs, C and E, in phosphate buffered saline (PBS). Here we continue to explore the mechanistic aspects of RSA by examining the thermodynamics of both mAbs under reduced pH and salt conditions.

Methods: Dynamic light scattering and sedimentation velocity (SV) studies were conducted for both mAbs at multiple protein concentrations and temperatures, with the SV data analyzed via global fitting to determine best-fit models, interaction energetics, and nonideality contributions.

Results: We find that mAb C self-associates isodesmically irrespective of temperature, and that association is enthalpically driven but entropically penalized. Conversely, mAb E self-associates cooperatively and via a monomer-dimer-tetramer-hexamer reaction pathway. Moreover, all mAb E reactions are entropically driven and enthalpically modest or minimal.

Conclusions: The thermodynamics for mAb C self-association are classically seen as originating from van der Waals interactions and hydrogen bonding. However, relative to the energetics we determined in PBS, self-association must also be linked to proton release and/or ion uptake events. For mAb E, the thermodynamics implicate electrostatic interactions. Furthermore, self-association is instead linked to proton uptake and/or ion release, and primarily by tetramers and hexamers. Finally, although the origins of mAb E cooperativity remain unclear, ring formation remains a possibility whereas linear polymerization reactions can be eliminated.

Citing Articles

Enabling Efficient Design of Biological Formulations through Advanced Characterizations.

Chen K, Cheung J, Kim H, Leone A, Mallela K, Su Y Pharm Res. 2023; 40(6):1313-1316.

PMID: 37407877 DOI: 10.1007/s11095-023-03557-2.

References
1.
Samaranayake H, Wirth T, Schenkwein D, Raty J, Yla-Herttuala S . Challenges in monoclonal antibody-based therapies. Ann Med. 2009; 41(5):322-31. DOI: 10.1080/07853890802698842. View

2.
Philo J, Arakawa T . Mechanisms of protein aggregation. Curr Pharm Biotechnol. 2009; 10(4):348-51. DOI: 10.2174/138920109788488932. View

3.
Shire S, Shahrokh Z, Liu J . Challenges in the development of high protein concentration formulations. J Pharm Sci. 2004; 93(6):1390-402. DOI: 10.1002/jps.20079. View

4.
Alford J, Kendrick B, Carpenter J, Randolph T . High concentration formulations of recombinant human interleukin-1 receptor antagonist: II. Aggregation kinetics. J Pharm Sci. 2007; 97(8):3005-21. DOI: 10.1002/jps.21205. View

5.
Nishi H, Miyajima M, Nakagami H, Noda M, Uchiyama S, Fukui K . Phase separation of an IgG1 antibody solution under a low ionic strength condition. Pharm Res. 2010; 27(7):1348-60. DOI: 10.1007/s11095-010-0125-7. View